his year’s biotech IPO waters are showing their first hints of turbulence.

Braeburn Pharmaceuticals, which last year got approval for an implant that dispenses medicine to treat opioid addiction, had planned to go public this week to raise up to $150 million. But on Thursday the company said in an emailed statement that it was scrapping its IPO plans for now, having “concluded that the current market environment does not represent an appropriate financing opportunity.”

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.